More specifically, we aim to estimate the effect of melanoma diagnosis on the subsequent risk of PC diagnosis while accounting for frequency of prostate-specific antigen (PSA) testing and general practitioner (GP) consultations. This evidence concerns the gene KLK3 and pachyonychia congenita.